{
    "@context": {
        "schema": "https://schema.org/",
        "dct": "http://purl.org/dc/terms/",
        "hg": "https://hormuz.group/data/ns#"
    },
    "id": "hg:company:pars-darou-company",
    "identifier": "hg:company:pars-darou-company",
    "dataset_type": "entity_dataset",
    "entity_type": "company",
    "data_version": "2.0",
    "generated_by": "Hormuz Data Layer 0.2.1",
    "generated_at": "2026-07-04T02:51:17+00:00",
    "name": "Pars Darou Company",
    "slug": "pars-darou-company",
    "status": "publish",
    "url": "https://hormuz.group/companies/pars-darou-company/",
    "json_url": "https://hormuz.group/wp-content/uploads/hormuz-data/cpt/company/pars-darou-company.json",
    "rest_url": "https://hormuz.group/wp-json/hormuz-data/v1/cpt/company/pars-darou-company",
    "summary": "",
    "machine_summary": "Pars Darou Company Pars Darou Company is a listed pharmaceutical manufacturer in Tehran and one of Iran's established public-market healthcare companies. In the Hormuz Group company graph, it matters because it links domestic drug production, APIs and pharmaceutical materials, herbal and chemical medicines, healthcare distribution, and regulated consumer-health demand. Its listed status makes it useful for monitoring pharmaceutical-sector profitability, raw-material exposure, pricing policy, and the relationship between healthcare demand and capital-market disclosures. Pars Darou is relevant for investors assessing Iran's pharmaceutical manufacturing sector, domestic drug supply, listed healthcare exposure, import substitution, API dependence, and regulated pricing risk. It can support analysis of medicine availability, raw-material procurement, product registration, distributor relationships, and healthcare-sector margins. Due diligence should review updated financial statements, product portfolio, ownership by pharmaceutical investment groups, API sourcing, export activity, receivables, working capital, GMP compliance, and exposure to currency movements or reimbursement delays. Pars Darou Company manufactures chemical and herbal medicines, pharmaceutical products, active and auxiliary pharmaceutical materials, cosmetic and hygiene-related products, and selected medical-supply categories. Its operations support domestic pharmacy demand, healthcare distributors, therapeutic supply chains, import substitution, and regulated pharmaceutical manufacturing in Iran. province: Tehran industry: Healthcare & Pharma, Manufacturing, Pharmaceuticals market: Consumer Demand, Healthcare, Materials, Supply Chains challenges: Compliance, Import Dependence, Supply Shortage, Technology Gap company_type: Manufacturer city: Tehran",
    "published_at": "2026-06-28T20:21:36+00:00",
    "modified_at": "2026-06-28T20:21:36+00:00",
    "taxonomies": {
        "province": [
            {
                "id": 3,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/provinces/tehran/"
            }
        ],
        "industry": [
            {
                "id": 21,
                "name": "Healthcare & Pharma",
                "slug": "healthcare-pharma",
                "url": "https://hormuz.group/industry/healthcare-pharma/"
            },
            {
                "id": 16,
                "name": "Manufacturing",
                "slug": "manufacturing",
                "url": "https://hormuz.group/industry/manufacturing/"
            },
            {
                "id": 121,
                "name": "Pharmaceuticals",
                "slug": "pharmaceuticals",
                "url": "https://hormuz.group/industry/healthcare-pharma/pharmaceuticals/"
            }
        ],
        "market": [
            {
                "id": 34,
                "name": "Consumer Demand",
                "slug": "consumer-demand",
                "url": "https://hormuz.group/market/consumer-demand/"
            },
            {
                "id": 69,
                "name": "Healthcare",
                "slug": "healthcare",
                "url": "https://hormuz.group/market/consumer-demand/healthcare/"
            },
            {
                "id": 73,
                "name": "Materials",
                "slug": "materials",
                "url": "https://hormuz.group/market/enterprise-demand/materials/"
            },
            {
                "id": 76,
                "name": "Supply Chains",
                "slug": "supply-chains",
                "url": "https://hormuz.group/market/enterprise-demand/supply-chains/"
            }
        ],
        "challenges": [
            {
                "id": 164,
                "name": "Compliance",
                "slug": "compliance",
                "url": "https://hormuz.group/challenges/regulatory-barriers/compliance/"
            },
            {
                "id": 176,
                "name": "Import Dependence",
                "slug": "import-dependence",
                "url": "https://hormuz.group/challenges/market-gaps/import-dependence/"
            },
            {
                "id": 177,
                "name": "Supply Shortage",
                "slug": "supply-shortage",
                "url": "https://hormuz.group/challenges/market-gaps/supply-shortage/"
            },
            {
                "id": 179,
                "name": "Technology Gap",
                "slug": "technology-gap",
                "url": "https://hormuz.group/challenges/market-gaps/technology-gap/"
            }
        ],
        "company_type": [
            {
                "id": 299,
                "name": "Manufacturer",
                "slug": "manufacturer",
                "url": "https://hormuz.group/company-type/manufacturer/"
            }
        ],
        "city": [
            {
                "id": 384,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/cities/tehran/"
            }
        ]
    },
    "taxonomy_labels": {
        "province": "Tehran",
        "industry": "Healthcare & Pharma, Manufacturing, Pharmaceuticals",
        "market": "Consumer Demand, Healthcare, Materials, Supply Chains",
        "challenges": "Compliance, Import Dependence, Supply Shortage, Technology Gap",
        "company_type": "Manufacturer",
        "city": "Tehran"
    },
    "fields_summary": {
        "legal_name": "Pars Darou Company Public Joint Stock Company",
        "website": "https://parsdarou.ir",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "دپارس",
        "listing_status": "listed_tse",
        "products_services": "Pars Darou Company manufactures chemical and herbal medicines, pharmaceutical products, active and auxiliary pharmaceutical materials, cosmetic and hygiene-related products, and selected medical-supply categories. Its operations support domestic pharmacy demand, healthcare distributors, therapeutic supply chains, import substitution, and regulated pharmaceutical manufacturing in Iran.",
        "export_relevance": "medium",
        "short_profile": "Pars Darou Company is a listed pharmaceutical manufacturer in Tehran and one of Iran's established public-market healthcare companies. In the Hormuz Group company graph, it matters because it links domestic drug production, APIs and pharmaceutical materials, herbal and chemical medicines, healthcare distribution, and regulated consumer-health demand. Its listed status makes it useful for monitoring pharmaceutical-sector profitability, raw-material exposure, pricing policy, and the relationship between healthcare demand and capital-market disclosures.",
        "investment_relevance": "Pars Darou is relevant for investors assessing Iran's pharmaceutical manufacturing sector, domestic drug supply, listed healthcare exposure, import substitution, API dependence, and regulated pricing risk. It can support analysis of medicine availability, raw-material procurement, product registration, distributor relationships, and healthcare-sector margins. Due diligence should review updated financial statements, product portfolio, ownership by pharmaceutical investment groups, API sourcing, export activity, receivables, working capital, GMP compliance, and exposure to currency movements or reimbursement delays."
    },
    "fields": {
        "rank_math_internal_links_processed": "1",
        "wp_statistics_words_count": "0",
        "legal_name": "Pars Darou Company Public Joint Stock Company",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "دپارس",
        "export_relevance": "medium",
        "verification_status": "basic",
        "data_confidence": "high",
        "listing_status": "listed_tse",
        "last_updated": "28/06/2026",
        "website": "https://parsdarou.ir",
        "products_services": "Pars Darou Company manufactures chemical and herbal medicines, pharmaceutical products, active and auxiliary pharmaceutical materials, cosmetic and hygiene-related products, and selected medical-supply categories. Its operations support domestic pharmacy demand, healthcare distributors, therapeutic supply chains, import substitution, and regulated pharmaceutical manufacturing in Iran.",
        "short_profile": "Pars Darou Company is a listed pharmaceutical manufacturer in Tehran and one of Iran's established public-market healthcare companies. In the Hormuz Group company graph, it matters because it links domestic drug production, APIs and pharmaceutical materials, herbal and chemical medicines, healthcare distribution, and regulated consumer-health demand. Its listed status makes it useful for monitoring pharmaceutical-sector profitability, raw-material exposure, pricing policy, and the relationship between healthcare demand and capital-market disclosures.",
        "investment_relevance": "Pars Darou is relevant for investors assessing Iran's pharmaceutical manufacturing sector, domestic drug supply, listed healthcare exposure, import substitution, API dependence, and regulated pricing risk. It can support analysis of medicine availability, raw-material procurement, product registration, distributor relationships, and healthcare-sector margins. Due diligence should review updated financial statements, product portfolio, ownership by pharmaceutical investment groups, API sourcing, export activity, receivables, working capital, GMP compliance, and exposure to currency movements or reimbursement delays.",
        "source_note": "Based on public company, official-company, pharmaceutical-sector, market, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
    },
    "field_profile": {
        "rank_math_internal_links_processed": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "wp_statistics_words_count": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "legal_name": {
            "type": "string",
            "present": true,
            "length": 45
        },
        "city": {
            "type": "string",
            "present": true,
            "length": 29
        },
        "ticker_symbol": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "export_relevance": {
            "type": "string",
            "present": true,
            "length": 6
        },
        "verification_status": {
            "type": "string",
            "present": true,
            "length": 5
        },
        "data_confidence": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "listing_status": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "last_updated": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "website": {
            "type": "string",
            "present": true,
            "length": 20
        },
        "products_services": {
            "type": "string",
            "present": true,
            "length": 387
        },
        "short_profile": {
            "type": "string",
            "present": true,
            "length": 556
        },
        "investment_relevance": {
            "type": "string",
            "present": true,
            "length": 622
        },
        "source_note": {
            "type": "string",
            "present": true,
            "length": 208
        }
    },
    "sources": [
        {
            "type": "note",
            "value": "Based on public company, official-company, pharmaceutical-sector, market, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
        }
    ],
    "quality": {
        "required_fields": [
            "legal_name",
            "website",
            "city",
            "listing_status",
            "products_services",
            "export_relevance",
            "verification_status",
            "data_confidence",
            "short_profile",
            "investment_relevance",
            "source_note",
            "last_updated"
        ],
        "missing_required_fields": [],
        "missing_required_count": 0,
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "28/06/2026",
        "stale_over_180_days": false,
        "quality_score": 100
    },
    "verification": {
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "28/06/2026"
    }
}